Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Phase II trial of lenalidomide in patients with metastatic renal cell carcinoma.

Literature DB >> 18161005

Phase II trial of lenalidomide in patients with metastatic renal cell carcinoma.

Premal H Patel¹, G Varuni Kondagunta, Lawrence Schwartz, Nicole Ishill, Jennifer Bacik, John DeLuca, Paul Russo, Robert J Motzer.

Abstract

Lenalidomide (CC-5013) is a structural derivative of thalidomide, with antiangiogenic and immunomodulatory effects. Fourteen patients with metastatic renal cell carcinoma (RCC) were enrolled on a phase 2 trial of lenalidomide administered orally at 25 mg daily for 21 days followed by a rest period of 7 days. The best response was stable disease in eight patients (57%) of the 14 evaluable patients. Toxicities included fatigue, hyperglycemia, dyspnea, and myelosuppression with decreased hemoglobin, lymphopenia, and neutropenia. Lenalidomide is tolerable, but no objective responses were observed in this clinical trial.

Entities: Chemical Disease Species

Mesh：

Substances：

Year: 2007 PMID： 18161005 DOI： 10.1007/s10637-007-9107-y

Source DB: PubMed Journal: Invest New Drugs ISSN： 0167-6997 Impact factor: 3.850

16 in total

Review 1. Thalidomide and lenalidomide in the treatment of multiple myeloma.

Authors: Shaji Kumar; S Vincent Rajkumar
Journal: Eur J Cancer Date: 2006-06-05 Impact factor: 9.162

Review 2. Renal-cell carcinoma.

Authors: R J Motzer; N H Bander; D M Nanus
Journal: N Engl J Med Date: 1996-09-19 Impact factor: 91.245

3. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma.

Authors: Robert J Motzer; Thomas E Hutson; Piotr Tomczak; M Dror Michaelson; Ronald M Bukowski; Olivier Rixe; Stéphane Oudard; Sylvie Negrier; Cezary Szczylik; Sindy T Kim; Isan Chen; Paul W Bycott; Charles M Baum; Robert A Figlin
Journal: N Engl J Med Date: 2007-01-11 Impact factor: 91.245

4. Optimal two-stage designs for phase II clinical trials.

Authors: R Simon
Journal: Control Clin Trials Date: 1989-03

5. Phase II trial of thalidomide for patients with advanced renal cell carcinoma.

Authors: Robert J Motzer; William Berg; Michelle Ginsberg; Paul Russo; Jacqueline Vuky; Richard Yu; Jennifer Bacik; Madhu Mazumdar
Journal: J Clin Oncol Date: 2002-01-01 Impact factor: 44.544

6. Phase II trial of thalidomide in renal-cell carcinoma.

Authors: B Escudier; N Lassau; D Couanet; E Angevin; F Mesrati; S Leborgne; A Garofano; C Leboulaire; N Dupouy; A Laplanche
Journal: Ann Oncol Date: 2002-07 Impact factor: 32.976

7. A pilot study of thalidomide in patients with progressive metastatic renal cell carcinoma.

Authors: Danai D Daliani; Christos N Papandreou; Peter F Thall; Xuemei Wang; Cherie Perez; Rose Oliva; Lance Pagliaro; Robert Amato
Journal: Cancer Date: 2002-08-15 Impact factor: 6.860

8. A phase II study of thalidomide in advanced metastatic renal cell carcinoma.

Authors: David R Minor; Dana Monroe; Lisa A Damico; Gloria Meng; Uma Suryadevara; Laurence Elias
Journal: Invest New Drugs Date: 2002-11 Impact factor: 3.850

9. Thalidomide is an inhibitor of angiogenesis.

Authors: R J D'Amato; M S Loughnan; E Flynn; J Folkman
Journal: Proc Natl Acad Sci U S A Date: 1994-04-26 Impact factor: 11.205

Review 10. Recent clinical studies of the immunomodulatory drug (IMiD) lenalidomide.

Authors: J B Bartlett; A Tozer; D Stirling; J B Zeldis
Journal: Br J Cancer Date: 2005-09-19 Impact factor: 7.640

9 in total

1. Phase I trial of lenalidomide in pediatric patients with recurrent, refractory, or progressive primary CNS tumors: Pediatric Brain Tumor Consortium study PBTC-018.

Authors: Katherine E Warren; Stewart Goldman; Ian F Pollack; Jason Fangusaro; Paula Schaiquevich; Clinton F Stewart; Dana Wallace; Susan M Blaney; Roger Packer; Tobey Macdonald; Regina Jakacki; James M Boyett; Larry E Kun
Journal: J Clin Oncol Date: 2010-12-13 Impact factor: 44.544

2. Updates on novel therapies for metastatic renal cell carcinoma.

Authors: Kevin D Courtney; Toni K Choueiri
Journal: Ther Adv Med Oncol Date: 2010-05 Impact factor: 8.168

3. Development and validation of a highly sensitive liquid chromatography/mass spectrometry method for simultaneous quantification of lenalidomide and flavopiridol in human plasma.

Authors: Qing Liu; Katherine L Farley; Amy J Johnson; Natarajan Muthusamy; Craig C Hofmeister; Kristie A Blum; Larry J Schaaf; Michael R Grever; John C Byrd; James T Dalton; Mitch A Phelps
Journal: Ther Drug Monit Date: 2008-10 Impact factor: 3.681

4. Phase I trial of docetaxel given every 3 weeks and daily lenalidomide in patients with advanced solid tumors.

Authors: Sharon L Sanborn; Joseph Gibbons; Smitha Krishnamurthi; Joanna M Brell; Afshin Dowlati; Joseph A Bokar; Charles Nock; Nancy Horvath; Jacob Bako; Scot C Remick; Matthew M Cooney
Journal: Invest New Drugs Date: 2008-11-15 Impact factor: 3.850

5. A phase I/II study of lenalidomide in combination with sunitinib in patients with advanced or metastatic renal cell carcinoma.

Authors: B Rini; B Redman; J A Garcia; H A Burris; S Li; A Fandi; R Beck; U Jungnelius; J R Infante
Journal: Ann Oncol Date: 2014-06-08 Impact factor: 32.976